Synairgen in Drug Partnership Talks After Study Results – Businessweek

Synairgen in Drug Partnership Talks After Study Results
Businessweek
Synairgen Plc (SNG) is in talks with potential partners following the results of a study of an experimental medicine targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said. Synairgen is speaking with larger
New drug 'stops common cold asthma deaths'Hayling Islander

all 3 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.